Coronarin D attenuates MPTP-induced Parkinson’s disease in mice by inhibition of oxidative stress and apoptosis

Abstract

Parkinson’s disease (PD) is a brain-related disease condition, globally it is the second most common neurodegenerative disease that mostly disturbs the brain motor control and action of the aged populations. It involves a tiny, dark portion of the brain denoted as substantia nigra. Dopamine is produced in the substantia nigra for the usage of the brain. This dopamine communicates messages among nerves and controls muscle movements. Coronarin D is a diterpenoid with exclusive pharmacological possessions and its effectiveness over a few neurogenerative diseases exposed to some intense properties. The present study was intended to exhibit the neuroprotective efficacy of Coronarin D over MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced animals. Oral management of Coronarin D (10 and 20 mg/kg body wt.) protects the MPTP-induced nigrostriatal dopamine (DA) depletion and its intermediate substances. Behavioral studies like narrow beam walk test, open field test and hang test were conducted to study the movement and actions of Coronarin D treated MPTP induced experimental animals, in which Coronarin D treated group III & IV animals showed better behavioral alterations. Our compound as well attenuated MPTP persuaded oxidative pressure in experimental animals. Apoptotic marker studies displayed that management with Coronarin D upturned MPTP induced programmed cell death, which might be its anti-apoptotic properties. Ultimately to conclude, Coronarin D recovered oxidative pressure, neurochemical alterations, apoptosis, and functional irregularities in investigational mice and propose a potential approach to disease management of neurodegenerative and its related disease.